Cellectis S.A.. (1/3/17). "Press Release: Cellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT". New York, NY.

	Region	San Francisco, CA
	Country	United States (USA)
	Organisation	Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
	Group	Cellectis (Group)
	Organisation 2	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 35th Annual Healthcare Conference 2017 San Francisco
	Product 2	TALEN® technology (Transcription Activator-Like Effector Nuclease)
	Index term	Cellectis–JPMorgan Chase: investor conference, 201701 supply service Cellectis presents at JP Morgan Healthcare Conference 2017
	Person	Choulika, André (Cellectis 200701 CEO + Co-Founder)
	Person 2	Harnest, Simon (Metagenomi 202107– Chief Investment Officer + SVP Strategy before Cellectis + Trout Group)

Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that Dr. André Choulika, Chairman and Chief Executive Officer of Cellectis, will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00 a.m. Pacific Time in the Elizabethan A/B room. The conference will be held from January 9 to 12, 2017 at the Westin St. Francis in San Francisco.

To access the live webcast of Cellectis’ presentation and subsequent breakout session, please visit http://www.cellectis.com/en/events. A replay of the webcast will be available on Cellectis’ website for 90 days.

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genomeengineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

For further information, please contact:

Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com

IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

# # #

Record changed: 2023-06-05